Evidence map›Paper›PMID 35901098›Full record

ArticlePloS one2022

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.

Takahiro Wakasaki, Tomomi Manako, Ryuji Yasumatsu, Hirotaka Hara, Satoshi Toh, Muneyuki Masuda, Moriyasu Yamauchi, Yuichiro Kuratomi, Emi Nishimura, Toranoshin Takeuchi and 5 more

Erratum issuedOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Preliminary observations on peripheral inflammatory markers in NIR-PIT and ICI-treated recurrent head and neck squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Takahiro WakasakiDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0001-7736-9162
Tomomi ManakoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryuji YasumatsuDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-5765-9418
Hirotaka HaraDepartment of Head and Neck Surgery, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
Satoshi TohDepartment of Head and Neck Surgery, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
Muneyuki MasudaDepartment of Head and Neck Surgery, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
Moriyasu YamauchiDepartment of Otolaryngology, Head and Neck Surgery, Saga University Hospital, Saga, Japan.ORCID 0000-0002-7719-4187
Yuichiro KuratomiDepartment of Otolaryngology, Head and Neck Surgery, Saga University Hospital, Saga, Japan.
Emi NishimuraDepartment of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Toranoshin TakeuchiDepartment of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Mioko MatsuoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Rina JiromaruDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kazuki HashimotoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Noritaka KomuneDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takashi NakagawaDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyushu University · JPNational Hospital Organization Kyushu Cancer Center · JPKitakyushu Municipal Medical Center · JPSaga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe benefit of sequential therapy after immune checkpoint inhibitor (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI administration. MATERIALS AND

methodsWe retrospectively reviewed the medical records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], n = 7, or weekly PTX and Cmab [PC], n = 45).

resultsThe objective response rate (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 42.9% and 57.1% in the PTX group, respectively. There was a significant difference in the DCR between the PC and PTX groups (p = 0.0143). The overall survival (OS) and progression-free survival were significantly better in the PC group than in the PTX group. On the other hand, the incidence of drug-induced interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. Patients in the PC group were divided according to whether they received Cmab (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. Group B had a significantly better OS than Group A. Furthermore, our findings suggest that the incidence rate of DI-IP during SCT might be higher in Group B.

conclusionAlthough PC following ICIs shows dramatic efficacy, careful monitoring of AEs, including DI-IP, is recommended.

Indexed as

CetuximabHead and Neck NeoplasmsImmune Checkpoint InhibitorsPaclitaxelAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasm Recurrence, LocalRetrospective StudiesSquamous Cell Carcinoma of Head and NeckCetuximabImmune Checkpoint InhibitorsPaclitaxel

Identifiers

PMID35901098
PMCPMC9333293
OpenAlexW4288431139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.